Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Cellply logo — Unravelling immune system function, one cell at a time

Cellply

Unravelling immune system function, one cell at a time

Founded 2013 Italy Italy 34 employees Total: $17.44M Biotechnology, Health Care

General Information

Company Name Cellply
Founded Year 2013
Location Italy Italy
Employees 34
Industries Biotechnology, Health Care
Social

BounceWatch is an independent company data service, not affiliated with Cellply. To contact Cellply, visit cellply.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Cellply compare?

A PDF of Cellply and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Cellply soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Cellply

Cellply is a biotechnology startup based in Italy, founded in 2013. The company's slogan "Unravelling immune system function, one cell at a time" reflects its core mission. Cellply is focused on developing next-generation analytical tools for in-depth characterization of cancer immunotherapies, cell therapies, and cell-based biotherapeutics. The company aims to accelerate research and development, advance quality control, and monitor clinical responses to novel cancer immunotherapies. Cellply achieves this through the use of proprietary microfluidic technologies, highly-automated analytical instruments, and AI-powered image and data analytics. The Cellply platform is designed to define the function of the immune system one cell at a time, combining functional data with other multiplex data, offering an unprecedented single-cell analytical solution. Notably, Cellply recently secured a $3.60M Venture Round investment on 27 September 2023, with participation from LIFTT, RECOMEC, and Schia Ventures. This latest investment signifies growing interest and potential in the promising work that Cellply is undertaking within the life-science industry.

Business keywords: life science, analytical tools, cancer immunotherapies, cell therapies, biotherapeutics, R&D acceleration, clinical response monitoring, microfluidic technologies, AI-powered analytics, single-cell analysis, Co-Culture Array technology, drug testing, potency evaluation, immune system function

Funding Rounds & Investors (7)

View All
Funding Stage Amount Investors Lead Investors Date
Round €7.15M 5
LIFTT
LIFTT, ENEA Tech e Biomedical +3
11 May 2026
Venture Round $3.60M 3
LIFTT
LIFTT, Schia Ventures +1
27 Sep 2023
Venture Round €2.00M 5
Indaco Venture Partners LIFTT Italian Angels for Growth
Indaco Venture Partners, LIFTT +3
15 Dec 2021
Grant €300.00K -
22 Nov 2018
Grant €2.34M 1
Horizon 2020
25 May 2018
Grant €50.00K 1
EASME - EU Executive Agency for SMEs
01 Dec 2016
Seed Round €2.00M 3
Indaco Venture Partners Italian Angels for Growth
Indaco Venture Partners, Italian Angels for Growth +1
20 Mar 2014

Latest News

View All
Bologna’s Cellply secures €7.15 million to develop tools for faster immunotherapy and cell therapy d... — Eu-startups
Bologna’s Cellply secures €7.15 million to develop tools for faster immunotherapy and cell therapy development
Eu-startups May 11, 2026
Bologna Gathering showcases Italy’s rising innovation momentum — Tech
Bologna Gathering showcases Italy’s rising innovation momentum
Tech Oct 06, 2025
EIC Scaling Club'a katılan 72 teknoloji şirketi — Webrazzi
EIC Scaling Club'a katılan 72 teknoloji şirketi
Webrazzi Oct 21, 2024

Cellply Alternatives & Competitors

View All Alternatives
Cellply vs
Bruker Cellular Analysis
Bruker Cellular Analysis United States

Understand The Life of Single Cells

Series D
106 employees
Biotechnology, Health Care
Compare Cellply vs Bruker Cellular Analysis
Cellply vs
Avacta Therapeutics
Avacta Therapeutics United Kingdom

Expanding the reach of highly potent cancer therapies with the pre|CISION® platform.

Post-IPO Equity
48 employees
Biotechnology, Health Care
Compare Cellply vs Avacta Therapeutics
Cellply vs
xcellbio
xcellbio United States

Improving therapeutic performance for predictive clinical outcomes through in vitro microenvironment...

Corporate Round
29 employees
Biotechnology, Health Care
View all alternatives

FAQ About Cellply

Unravelling immune system function, one cell at a time
Cellply was founded in 2013.
Cellply is headquartered in Italy.
Cellply operates in Biotechnology and Health Care. Its work centres on life science, analytical tools, cancer immunotherapies and cell therapies.
Cellply has approximately 34 employees.
Cellply has completed 7 funding rounds, raising a total of $17.44M.
Top alternatives and competitors to Cellply include Bruker Cellular Analysis, Avacta Therapeutics, xcellbio, NextCure, Inc., Pear Bio. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Cellply and Bruker Cellular Analysis are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Cellply, https://bouncewatch.com/company/cellply, updated 11 May 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout